About Pfizer (NYSE:PFE)
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Industry, Sector and Symbol
Trailing P/E Ratio10.1424790384018
Forward P/E Ratio12.07
Sales & Book Value
Annual Sales$52.55 billion
Price / Sales4.03
Cash Flow$3.67 per share
Price / Cash9.69
Book Value$12.02 per share
Price / Book2.96
Net Income$21.31 billion
Return on Equity25.21%
Return on Assets9.42%
Pfizer (NYSE:PFE) Frequently Asked Questions
What is Pfizer's stock symbol?
Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."
How often does Pfizer pay dividends? What is the dividend yield for Pfizer?
Pfizer declared a quarterly dividend on Monday, December 18th. Stockholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share on Thursday, March 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.82%. The ex-dividend date of this dividend is Thursday, February 1st. This is an increase from Pfizer's previous quarterly dividend of $0.32. View Pfizer's Dividend History.
How will Pfizer's stock buyback program work?
Pfizer announced that its board has authorized a share repurchase program on Tuesday, December 19th 2017, which authorizes the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board believes its stock is undervalued.
How were Pfizer's earnings last quarter?
Pfizer Inc. (NYSE:PFE) issued its quarterly earnings data on Tuesday, January, 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.56 by $0.06. The biopharmaceutical company earned $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm's revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.47 EPS. View Pfizer's Earnings History.
When will Pfizer make its next earnings announcement?
What guidance has Pfizer issued on next quarter's earnings?
Pfizer issued an update on its FY18 earnings guidance on Tuesday, January, 30th. The company provided earnings per share guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.78. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $53.82 billion.
Where is Pfizer's stock going? Where will Pfizer's stock price be in 2018?
18 equities research analysts have issued twelve-month price objectives for Pfizer's shares. Their predictions range from $31.00 to $43.00. On average, they anticipate Pfizer's share price to reach $39.24 in the next twelve months. View Analyst Ratings for Pfizer.
What are Wall Street analysts saying about Pfizer stock?
Here are some recent quotes from research analysts about Pfizer stock:
- 1. According to Zacks Investment Research, "Pfizer is working on strengthening its product portfolio through acquisitions and licensing deals. Pfizer faces headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition which is hurting the top-line. Though Pfizer’s growing immuno-oncology portfolio offers strong potential, many of these assets are in early stage of development. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Bavencio is being considered a key long-term growth driver for Pfizer. Pfizer has a mixed record of earnings surprises in recent quarters. Estimates have gone up slightly ahead of its Q4 earnings release." (1/24/2018)
- 2. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)
Are investors shorting Pfizer?
Pfizer saw a increase in short interest in February. As of February 28th, there was short interest totalling 61,827,751 shares, an increase of 3.6% from the February 15th total of 64,127,631 shares. Based on an average trading volume of 23,715,494 shares, the days-to-cover ratio is presently 2.6 days. Approximately 1.0% of the company's shares are sold short.
Who are some of Pfizer's key competitors?
Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Roche (RHHBY), Novartis (NVS), AbbVie (ABBV), Merck & Co., Inc. (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), Sanofi (SNY), Gilead Sciences (GILD), Bayer (BAYRY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Celgene (CELG), Biogen (BIIB), Allergan (AGN) and Vertex Pharmaceuticals (VRTX).
Who are Pfizer's key executives?
Pfizer's management team includes the folowing people:
- Ian C. Read, Chairman of the Board, Chief Executive Officer (Age 63)
- Frank A. D'Amelio, Chief Financial Officer, Executive Vice President - Business Operations (Age 59)
- Mikael Dolsten M.D., Ph.D., President - Worldwide Research and Development (Age 58)
- Angela Hwang, Group President - Pfizer Essential Health (Age 52)
- John D. Young, Group President - Pfizer Innovative Health and Angela Hwang (Age 53)
- Albert Bourla, Chief Operating Officer, Director (Age 56)
- Rady A. Johnson II, Executive Vice President, Chief Compliance and Risk Officer (Age 55)
- Douglas M. Lankler, Executive Vice President, General Counsel (Age 51)
- Charles H. Hill III, Executive Vice President - Worldwide Human Resources (Age 61)
- Freda C. Lewis-Hall M.D., Executive Vice President, Chief Medical Officer (Age 62)
Has Pfizer been receiving favorable news coverage?
Headlines about PFE stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pfizer earned a news sentiment score of 0.06 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.94 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Pfizer's major shareholders?
Pfizer's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.60%), Bank of New York Mellon Corp (1.19%), Geode Capital Management LLC (1.06%), Franklin Resources Inc. (0.76%), Barrow Hanley Mewhinney & Strauss LLC (0.71%) and Fisher Asset Management LLC (0.61%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.
Which major investors are selling Pfizer stock?
PFE stock was sold by a variety of institutional investors in the last quarter, including Credit Agricole S A, Renaissance Technologies LLC, Pentwater Capital Management LP, Barrow Hanley Mewhinney & Strauss LLC, Metropolitan Life Insurance Co. NY, Assenagon Asset Management S.A., The Manufacturers Life Insurance Company and ING Groep NV. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.
Which major investors are buying Pfizer stock?
PFE stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Mackenzie Financial Corp, Amundi Pioneer Asset Management Inc., Bank of New York Mellon Corp, American Century Companies Inc., Sanders Capital LLC, MUFG Securities EMEA plc and Geode Capital Management LLC. View Insider Buying and Selling for Pfizer.
How do I buy shares of Pfizer?
Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pfizer's stock price today?
One share of PFE stock can currently be purchased for approximately $35.60.
How big of a company is Pfizer?
Pfizer has a market capitalization of $216.27 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $3.51 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.
How can I contact Pfizer?
Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.
MarketBeat Community Rating for Pfizer (PFE)MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pfizer (NYSE:PFE) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Buy||Buy|
|Consensus Rating Score: ||2.39||2.39||2.56||2.50|
|Ratings Breakdown: ||1 Sell Rating(s)|
9 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
9 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$39.24||$39.29||$38.60||$38.31|
|Price Target Upside: ||10.21% upside||10.16% upside||5.87% upside||8.07% upside|
Pfizer (NYSE:PFE) Consensus Price Target History
Pfizer (NYSE:PFE) Analyst Ratings History
(Data available from 3/22/2016 forward)
Pfizer (NYSE:PFE) Earnings History and Estimates Chart
Pfizer (NYSE PFE) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/30/2018||Q4 2017||$0.56||$0.62||$13.67 billion||$13.70 billion||View||Listen|
|10/31/2017||Q3 2017||$0.65||$0.67||$13.17 billion||$13.17 billion||View||N/A|
|8/1/2017||Q2 2017||$0.65||$0.67||$13.08 billion||$12.90 billion||View||Listen|
|5/2/2017||Q1 2017||$0.67||$0.69||$13.09 billion||$12.78 billion||View||Listen|
|1/31/2017||Q416||$0.50||$0.47||$13.64 billion||$13.60 billion||View||N/A|
|11/1/2016||Q3||$0.62||$0.61||$13.05 billion||$13.05 billion||View||N/A|
|8/2/2016||Q216||$0.62||$0.64||$13.01 billion||$13.10 billion||View||N/A|
|5/3/2016||Q116||$0.55||$0.67||$12.00 billion||$13.00 billion||View||N/A|
|2/2/2016||Q415||$0.52||$0.53||$13.57 billion||$14.05 billion||View||N/A|
|10/27/2015||Q315||$0.51||$0.60||$11.56 billion||$12.10 billion||View||Listen|
|7/28/2015||Q215||$0.52||$0.56||$11.39 billion||$11.00 billion||View||Listen|
|4/28/2015||Q115||$0.49||$0.51||$10.79 billion||$10.86 billion||View||N/A|
|1/27/2015||Q414||$0.53||$0.54||$12.94 billion||$13.10 billion||View||N/A|
|10/28/2014||Q314||$0.55||$0.57||$12.24 billion||$12.40 billion||View||N/A|
|7/29/2014||Q214||$0.57||$0.58||$12.49 billion||$12.80 billion||View||N/A|
|5/5/2014||Q114||$0.56||$0.57||$12.07 billion||$11.35 million||View||N/A|
|1/27/2014||Q413||$0.52||$0.56||$13.35 billion||$13.56 billion||View||N/A|
|10/29/2013||Q313||$0.56||$0.58||$12.69 billion||$12.64 billion||View||N/A|
|7/30/2013||Q2 2013||$0.55||$0.56||$13.02 billion||$12.97 billion||View||Listen|
|4/30/2013||Q1 2013||$0.55||$0.54||$14.10 billion||$13.50 billion||View||Listen|
|1/29/2013||Q4 2012||$0.44||$0.47||$14.40 billion||$15.10 billion||View||Listen|
|11/1/2012||Q312||$0.53||$0.53||$14.64 billion||$14.00 billion||View||N/A|
Pfizer (NYSE:PFE) Earnings Estimates
2018 EPS Consensus Estimate: $2.94
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Pfizer (NYSE:PFE) Dividend Information
|Most Recent Dividend:||3/1/2018|
|Dividend Growth:||7.20% (3 Year Average)|
|Payout Ratio:||38.75% (Trailing 12 Months of Earnings) |
46.10% (Based on This Year's Estimates)
44.88% (Based on Next Year's Estimates)
|Track Record:||8 Years of Consecutive Dividend Growth|
Pfizer (NYSE:PFE) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Pfizer (NYSE PFE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 71.16%
Pfizer (NYSE PFE) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/13/2018||Douglas M Lankler||Insider||Sell||50,000||$36.89||$1,844,500.00||133,057|| |
|3/13/2018||Rady A Johnson||EVP||Sell||27,323||$36.55||$998,655.65||70,332|| |
|3/9/2018||Mikael Dolsten||Insider||Sell||69,699||$36.59||$2,550,286.41||120,784|| |
|3/6/2018||Charles H Hill||Insider||Sell||42,393||$35.76||$1,515,973.68|| |
|3/2/2018||Mikael Dolsten||Insider||Sell||13,986||$35.85||$501,398.10||120,884|| |
|2/27/2018||Sally Susman||EVP||Sell||33,368||$37.03||$1,235,617.04||191,505|| |
|2/27/2018||W Don Cornwell||Director||Sell||1,758||$36.79||$64,676.82||1,000|| |
|2/26/2018||Kirsten Lund-Jurgensen||Insider||Sell||9,510||$37.19||$353,676.90||36,959|| |
|12/15/2017||Alexander R Mackenzie||Insider||Sell||6,750||$37.00||$249,750.00||103,458|| |
|12/15/2017||Rady A Johnson||EVP||Sell||8,000||$37.07||$296,560.00||46,963|| |
|11/1/2017||Alexander R Mackenzie||Insider||Sell||14,700||$35.30||$518,910.00||117,432|| |
|10/2/2017||Alexander R Mackenzie||EVP||Sell||7,350||$35.65||$262,027.50||117,432|| |
|9/12/2017||Sally Susman||Insider||Sell||38,230||$35.00||$1,338,050.00||145,649|| |
|9/1/2017||Alexander R Mackenzie||Insider||Sell||7,350||$34.00||$249,900.00||124,774|| |
|8/31/2017||Alexander R Mackenzie||Insider||Sell||7,350||$34.00||$249,900.00||132,124|| |
|8/31/2017||Frank A Damelio||EVP||Sell||94,409||$34.00||$3,209,906.00||337,389|| |
|8/31/2017||Ian C Read||CEO||Sell||197,168||$34.00||$6,703,712.00||580,318|| |
|8/21/2017||Laurie J Olson||Insider||Sell||8,064||$32.70||$263,692.80||74,506|| |
|8/7/2017||Alexander R Mackenzie||Insider||Sell||15,000||$33.50||$502,500.00||151,474|| |
|8/4/2017||Ian C. Read||CEO||Sell||96,950||$34.00||$3,296,300.00|| |
|3/10/2017||Rady A Johnson||Insider||Sell||4,500||$34.19||$153,855.00||54,963|| |
|3/9/2017||Charles H Hill||Insider||Sell||36,000||$34.07||$1,226,520.00||57,329|| |
|3/2/2017||Mikael Dolsten||Insider||Sell||30,970||$34.51||$1,068,774.70||64,719|| |
|11/9/2016||Anthony J Maddaluna||Insider||Sell||10,000||$33.00||$330,000.00||112,087|| |
|11/4/2016||Albert Bourla||Insider||Sell||18,390||$30.05||$552,619.50||149,199|| |
|5/26/2016||Frank A Damelio||EVP||Sell||100,000||$34.49||$3,449,000.00||472,994|| |
|5/24/2016||Loretta V Cangialosi||VP||Sell||86,000||$33.97||$2,921,420.00||271,663|| |
|5/11/2016||Laurie J Olson||EVP||Sell||4,700||$33.50||$157,450.00||71,659|| |
|5/10/2016||Frank A Damelio||EVP||Sell||192,000||$33.66||$6,462,720.00||564,994|| |
|5/10/2016||John D Young||Insider||Sell||41,700||$33.53||$1,398,201.00||200,399|| |
|5/9/2016||Anthony J Maddaluna||EVP||Sell||8,950||$33.75||$302,062.50||88,922|| |
|5/9/2016||Ian C Read||CEO||Sell||275,000||$33.80||$9,295,000.00||1,446,738|| |
|5/5/2016||Sally Susman||EVP||Sell||76,116||$33.75||$2,568,915.00||195,951|| |
|5/4/2016||Douglas M Lankler||EVP||Sell||29,700||$33.69||$1,000,593.00||124,920|| |
|5/4/2016||Mikael Dolsten||Insider||Sell||67,588||$33.46||$2,261,494.48||438,107|| |
|5/3/2016||Frank A Damelio||EVP||Sell||87,079||$33.65||$2,930,208.35||372,994|| |
|10/6/2015||Pfizer Inc||major shareholder||Buy||714,285||$7.00||$4,999,995.00||2,489,364|| |
|6/11/2015||Laurie J Olson||EVP||Sell||26,000||$34.39||$894,140.00|| |
|3/12/2015||Sally Susman||EVP||Sell||46,179||$34.00||$1,570,086.00|| |
|2/13/2015||Loretta V Cangialosi||VP||Sell||104,000||$34.73||$3,611,920.00|| |
|2/12/2015||Anthony J Maddaluna||EVP||Sell||9,000||$34.85||$313,650.00|| |
|2/11/2015||Frank A Damelio||EVP||Sell||14,800||$34.30||$507,640.00|| |
|2/10/2015||Anthony J Maddaluna||EVP||Sell||9,000||$33.78||$304,020.00|| |
|12/8/2014||Anthony J Maddaluna||EVP||Sell||6,500||$32.00||$208,000.00|| |
|11/10/2014||Charles H Hill||EVP||Sell||8,285||$30.18||$250,041.30|| |
|11/7/2014||John D Young||Insider||Sell||21,600||$29.89||$645,624.00|| |
|10/29/2014||Anthony J Maddaluna||EVP||Sell||2,425||$29.56||$71,683.00|| |
|6/12/2014||Laurie J Olson||EVP||Sell||36,275||$29.53||$1,071,200.75|| |
|6/2/2014||Geno J Germano||Insider||Sell||30,000||$29.68||$890,400.00|| |
|3/17/2014||John Young||Insider||Sell||9,000||$31.38||$282,420.00||99,647|| |
|3/4/2014||Loretta Cangialosi||VP||Sell||102,943||$32.05||$3,299,323.15||171,756|| |
|3/4/2014||Mikael Dolsten||Insider||Sell||35,789||$32.58||$1,166,005.62||344,571|| |
|3/4/2014||Sally Susman||EVP||Sell||67,585||$32.59||$2,202,595.15||173,637|| |
|1/13/2014||Frank Damelio||EVP||Sell||131,810||$30.82||$4,062,384.20||356,451|| |
|11/1/2013||Anthony J Maddaluna||EVP||Sell||43,500||$31.02||$1,349,370.00|| |
|11/1/2013||Loretta V Cangialosi||VP||Sell||10,000||$31.20||$312,000.00|| |
|10/28/2013||Ian C Read||CEO||Sell||338,000||$30.57||$10,332,660.00|| |
|9/16/2013||Freda Lewis-Hall||EVP||Sell||38,461||$28.70||$1,103,830.70||118,383|| |
|7/31/2013||Charles H Hill||EVP||Sell||96,500||$29.64||$2,860,260.00|| |
|7/31/2013||Loretta V Cangialosi||VP||Sell||14,688||$29.63||$435,205.44|| |
|5/15/2013||Amy W Schulman||EVP||Sell||70,000||$29.36||$2,055,200.00|| |
|5/15/2013||Ian C Read||CEO||Sell||69,900||$29.39||$2,054,361.00|| |
Pfizer (NYSE PFE) News Headlines
Pfizer (NYSE:PFE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pfizer (NYSE:PFE) Income Statement, Balance Sheet and Cash Flow Statement
Pfizer (NYSE PFE) Stock Chart for Thursday, March, 22, 2018